View Financial HealthNipro 配当と自社株買い配当金 基準チェック /36Nipro配当を支払う会社であり、現在の利回りは2.49%で、収益によって十分にカバーされています。主要情報2.5%配当利回り0.02%バイバック利回り総株主利回り2.5%将来の配当利回り2.6%配当成長-3.7%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向87%最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Aug 01Nipro Corporation Receives Fda 510(K) Clearance for Elisio-Hx Dialyzer and Introduces Hds to the United StatesNIPRO CORPORATION has been granted 510(k) clearance for the ELISIO-HX dialyzer by the United States Food and Drug Administration (FDA), effective July 28, 2026. The clearance enables the introduction of HDs (Hemodialysis powered by super high-flux membrane) in the United States. HDs is NIPRO's approach within expanded hemodialysis (Expanded HD), providing healthcare professionals with a practical way to enhance hemodialysis while using existing dialysis infrastructure and established clinical workflows. ELISIO-HX has been developed to address this need through an approach designed for broad patient eligibility and straightforward integration into routine dialysis care. At the core of HDs is the ELISIO-HX dialyzer, featuring NIPRO's proprietary super high-flux membrane technology. The membrane incorporates a highly controlled and precisely engineered pore structure that extends the removal profile of larger middle molecules while maintaining albumin retention, an important consideration in preserving patients' nutritional status. This precision-engineered membrane design enables healthcare professionals to enhance dialysis treatment while remaining fully compatible with conventional hemodialysis systems. Because ELISIO-HX integrates into existing hemodialysis infrastructure and established clinical workflows, providers can adopt HDs without investing in new dialysis machines or fundamentally changing the way dialysis is delivered. The introduction of HDs to the United States market builds on clinical and real-world experience with ELISIO-HX across Japan, Europe and Latin America, demonstrating its applicability in a variety of healthcare settings. With the 510(k) clearance, NIPRO will begin the commercialization of ELISIO-HX in the United States immediately. NIPRO will work closely with healthcare providers to support the successful introduction of HDs into routine clinical practice.お知らせ • Jul 30Vat Holding AG signed a letter of intent to acquire an unknown minority stake in Atonarp Inc. from Nipro Corporation (TSE:8086).Vat Holding AG signed a letter of intent to acquire an unknown stake in Atonarp Inc. from Nipro Corporation (TSE:8086) on July 29, 2026. The amount may fluctuate due to adjustments to additions to or deductions from the purchase prior to closing. Scheduled sale date is between August and October 2026.お知らせ • Jun 03Nipro Corporation to Report Q1, 2027 Results on Aug 10, 2026Nipro Corporation announced that they will report Q1, 2027 results on Aug 10, 2026お知らせ • May 12Nipro Corporation, Annual General Meeting, Jun 26, 2026Nipro Corporation, Annual General Meeting, Jun 26, 2026.お知らせ • Mar 09Nipro Corporation to Report Fiscal Year 2026 Final Results on May 12, 2026Nipro Corporation announced that they will report fiscal year 2026 final results on May 12, 2026お知らせ • Dec 17Nipro Corporation to Report Q3, 2026 Results on Feb 09, 2026Nipro Corporation announced that they will report Q3, 2026 results on Feb 09, 2026お知らせ • Sep 30Nipro Corporation to Report Q2, 2026 Results on Nov 10, 2025Nipro Corporation announced that they will report Q2, 2026 results on Nov 10, 2025お知らせ • Jun 03Nipro Corporation to Report Q1, 2026 Results on Aug 08, 2025Nipro Corporation announced that they will report Q1, 2026 results on Aug 08, 2025お知らせ • May 12+ 3 more updatesNipro Corporation, Annual General Meeting, Jun 26, 2025Nipro Corporation, Annual General Meeting, Jun 26, 2025.お知らせ • Mar 04Nipro Corporation to Report Fiscal Year 2025 Results on May 12, 2025Nipro Corporation announced that they will report fiscal year 2025 results at 12:00 PM, Tokyo Standard Time on May 12, 2025お知らせ • Dec 03Nipro Corporation to Report Q3, 2025 Results on Feb 07, 2025Nipro Corporation announced that they will report Q3, 2025 results on Feb 07, 2025お知らせ • Aug 29Nipro Corporation to Report Q2, 2025 Results on Nov 08, 2024Nipro Corporation announced that they will report Q2, 2025 results on Nov 08, 2024お知らせ • Dec 01Nipro Corporation to Report Q3, 2023 Results on Feb 08, 2023Nipro Corporation announced that they will report Q3, 2023 results on Feb 08, 2023決済の安定と成長配当データの取得安定した配当: NPRR.Fの配当金支払いは、過去10年間 変動性 が高かった。増加する配当: NPRR.Fの配当金は過去10年間にわたって増加しています。配当利回り対市場Nipro 配当利回り対市場NPRR.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (NPRR.F)2.5%市場下位25% (US)1.3%市場トップ25% (US)4.0%業界平均 (Medical Equipment)1.9%アナリスト予想 (NPRR.F) (最長3年)2.6%注目すべき配当: NPRR.Fの配当金 ( 2.49% ) はUS市場の配当金支払者の下位 25% ( 1.3% ) よりも高くなっています。高配当: NPRR.Fの配当金 ( 2.49% ) はUS市場の配当金支払者の上位 25% ( 4% ) と比較すると低いです。株主への利益配当収益カバレッジ: 現在の配当性向（ 86.8% ）では、 NPRR.Fの支払いは利益によってカバーされています。株主配当金キャッシュフローカバレッジ: NPRR.Fは配当金を支払っていますが、同社にはフリーキャッシュフローがありません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/05/12 18:03終値2025/02/12 00:00収益2024/12/31年間収益2024/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Nipro Corporation 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13 アナリスト機関Masahiro NakanomyoBarclaysYuki YamazakiDaiwa Securities Co. Ltd.Stephen BarkerJefferies LLC10 その他のアナリストを表示
お知らせ • Aug 01Nipro Corporation Receives Fda 510(K) Clearance for Elisio-Hx Dialyzer and Introduces Hds to the United StatesNIPRO CORPORATION has been granted 510(k) clearance for the ELISIO-HX dialyzer by the United States Food and Drug Administration (FDA), effective July 28, 2026. The clearance enables the introduction of HDs (Hemodialysis powered by super high-flux membrane) in the United States. HDs is NIPRO's approach within expanded hemodialysis (Expanded HD), providing healthcare professionals with a practical way to enhance hemodialysis while using existing dialysis infrastructure and established clinical workflows. ELISIO-HX has been developed to address this need through an approach designed for broad patient eligibility and straightforward integration into routine dialysis care. At the core of HDs is the ELISIO-HX dialyzer, featuring NIPRO's proprietary super high-flux membrane technology. The membrane incorporates a highly controlled and precisely engineered pore structure that extends the removal profile of larger middle molecules while maintaining albumin retention, an important consideration in preserving patients' nutritional status. This precision-engineered membrane design enables healthcare professionals to enhance dialysis treatment while remaining fully compatible with conventional hemodialysis systems. Because ELISIO-HX integrates into existing hemodialysis infrastructure and established clinical workflows, providers can adopt HDs without investing in new dialysis machines or fundamentally changing the way dialysis is delivered. The introduction of HDs to the United States market builds on clinical and real-world experience with ELISIO-HX across Japan, Europe and Latin America, demonstrating its applicability in a variety of healthcare settings. With the 510(k) clearance, NIPRO will begin the commercialization of ELISIO-HX in the United States immediately. NIPRO will work closely with healthcare providers to support the successful introduction of HDs into routine clinical practice.
お知らせ • Jul 30Vat Holding AG signed a letter of intent to acquire an unknown minority stake in Atonarp Inc. from Nipro Corporation (TSE:8086).Vat Holding AG signed a letter of intent to acquire an unknown stake in Atonarp Inc. from Nipro Corporation (TSE:8086) on July 29, 2026. The amount may fluctuate due to adjustments to additions to or deductions from the purchase prior to closing. Scheduled sale date is between August and October 2026.
お知らせ • Jun 03Nipro Corporation to Report Q1, 2027 Results on Aug 10, 2026Nipro Corporation announced that they will report Q1, 2027 results on Aug 10, 2026
お知らせ • May 12Nipro Corporation, Annual General Meeting, Jun 26, 2026Nipro Corporation, Annual General Meeting, Jun 26, 2026.
お知らせ • Mar 09Nipro Corporation to Report Fiscal Year 2026 Final Results on May 12, 2026Nipro Corporation announced that they will report fiscal year 2026 final results on May 12, 2026
お知らせ • Dec 17Nipro Corporation to Report Q3, 2026 Results on Feb 09, 2026Nipro Corporation announced that they will report Q3, 2026 results on Feb 09, 2026
お知らせ • Sep 30Nipro Corporation to Report Q2, 2026 Results on Nov 10, 2025Nipro Corporation announced that they will report Q2, 2026 results on Nov 10, 2025
お知らせ • Jun 03Nipro Corporation to Report Q1, 2026 Results on Aug 08, 2025Nipro Corporation announced that they will report Q1, 2026 results on Aug 08, 2025
お知らせ • May 12+ 3 more updatesNipro Corporation, Annual General Meeting, Jun 26, 2025Nipro Corporation, Annual General Meeting, Jun 26, 2025.
お知らせ • Mar 04Nipro Corporation to Report Fiscal Year 2025 Results on May 12, 2025Nipro Corporation announced that they will report fiscal year 2025 results at 12:00 PM, Tokyo Standard Time on May 12, 2025
お知らせ • Dec 03Nipro Corporation to Report Q3, 2025 Results on Feb 07, 2025Nipro Corporation announced that they will report Q3, 2025 results on Feb 07, 2025
お知らせ • Aug 29Nipro Corporation to Report Q2, 2025 Results on Nov 08, 2024Nipro Corporation announced that they will report Q2, 2025 results on Nov 08, 2024
お知らせ • Dec 01Nipro Corporation to Report Q3, 2023 Results on Feb 08, 2023Nipro Corporation announced that they will report Q3, 2023 results on Feb 08, 2023